In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474.
Antineoplastic Agents, Immunological
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ drug therapy
Caspase 3
/ metabolism
Cell Line, Tumor
Cell Survival
/ drug effects
Drug Resistance, Neoplasm
Female
Humans
Microscopy, Electron, Scanning
Organoselenium Compounds
/ pharmacology
Oxidation-Reduction
Receptor, ErbB-2
/ metabolism
Selenium
/ pharmacology
Superoxides
/ metabolism
Trastuzumab
/ pharmacology
Herceptin®
Kadcyla® (T-DM-1)
Trastuzumab (Tz)
antibody drug conjugate (ADC)
epidermal growth factor receptor (EGFR)
human epidermal growth factor receptor 2 (Her/2)
monoclonal antibody (mab)
reduced glutathione (GSH)
selenium (Se)
superoxide (O2•−)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Apr 2021
28 Apr 2021
Historique:
received:
25
03
2021
revised:
20
04
2021
accepted:
22
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Her/2+ breast cancer accounts for ~25% mortality in women and overexpression of Her/2 leads to cell growth and tumor progression. Trastuzumab (Tz) with Taxane is the preferred treatment for Her/2+ patients. However, Tz responsive patients often develop resistance to Tz treatment. Herein, redox selenides (RSe-) were covalently linked to Tz using a selenium (Se)-modified Bolton-Hunter Reagent forming Seleno-Trastuzumab (Se-Tz; ~25 µgSe/mg). Se-Tz was compared to Tz and sodium selenite to assess the viability of JIMT-1 and BT-474 cells. Comparative cell viability was examined by microscopy and assessed by fluorometric/enzymatic assays. Se-Tz and selenite redox cycle producing superoxide (O
Identifiants
pubmed: 33925081
pii: ijms22094655
doi: 10.3390/ijms22094655
pmc: PMC8124313
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Organoselenium Compounds
0
Superoxides
11062-77-4
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
CASP3 protein, human
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Selenium
H6241UJ22B
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Drugs. 2013 May;73(7):755-65
pubmed: 23620199
J Biol Chem. 1993 Sep 5;268(25):18407-10
pubmed: 7689552
Semin Oncol. 2001 Feb;28(1 Suppl 3):13-9
pubmed: 11301370
Int J Mol Sci. 2018 Oct 26;19(11):
pubmed: 30373175
Biomed Environ Sci. 1997 Sep;10(2-3):333-9
pubmed: 9315327
Biochemistry. 1973 Nov 6;12(23):4586-90
pubmed: 4773846
Lancet. 1986 Apr 5;1(8484):765-7
pubmed: 2870269
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9193-7
pubmed: 2687875
Biofactors. 2007;31(1):55-66
pubmed: 18806309
Drugs Today (Barc). 1999 Dec;35(12):931-46
pubmed: 12973420
J Clin Oncol. 2000 Feb;18(4):904-14
pubmed: 10673534
Nature. 1978 Nov 23;276(5686):409-10
pubmed: 309559
Nat Biotechnol. 1998 Jul;16(7):615
pubmed: 9661186
Oncogene. 2007 May 28;26(25):3637-43
pubmed: 17530017
Cancer Cell. 2002 Mar;1(2):117-23
pubmed: 12086869
Nat Clin Pract Oncol. 2006 May;3(5):269-80
pubmed: 16683005
Curr Protoc Neurosci. 2001 May;Appendix 3:Appendix 3A
pubmed: 18428448
Arch Biochem Biophys. 1992 Jul;296(1):328-36
pubmed: 1605642
Nature. 1984 May 31-Jun 6;309(5967):418-25
pubmed: 6328312
Free Radic Biol Med. 1994 Jul;17(1):45-64
pubmed: 7959166
Cancer Res. 2005 Jan 15;65(2):473-82
pubmed: 15695389
J Clin Oncol. 2010 Jun 1;28(16):2698-704
pubmed: 20421541
Biochem J. 1973 Jul;133(3):529-39
pubmed: 4733239
Int J Breast Cancer. 2011;2011:352182
pubmed: 22295219
Clin Breast Cancer. 2011 Oct;11(5):275-82
pubmed: 21729661
Biochem Pharmacol. 1993 Jan 26;45(2):429-37
pubmed: 8382065